Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Torvutatug samrotecan + Bevacizumab in advanced ovarian cancer
NCT07851025Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2026
- Primary completion
- Jun 2030
- Countries
- 24
01
Overview
A Phase 3 trial of torvutatug samrotecan in epithelial ovarian cancer (EOC), sponsored by AstraZeneca. Started Sep 2026; status: recruiting.
02
Drugs
torvutatug samrotecan
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on NCT07851025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07851025.